Biomarin Pharmaceutical (BMRN) Current Assets (2009 - 2026)

Biomarin Pharmaceutical has disclosed Current Assets across 18 years of filings, most recently posting $4.6 billion for Q1 2026.

• Quarterly Current Assets rose 32.79% year-over-year to $4.6 billion in Q1 2026, while the trailing twelve-month figure through Mar 2026 was $4.6 billion (up 32.79% YoY) and the FY2025 annual result came in at $4.0 billion, up 22.31% from the prior year.
• Current Assets rose to $4.6 billion in Q1 2026, from $4.0 billion in the prior quarter.
• Over five years, Current Assets peaked at $4.6 billion in Q1 2026 and troughed at $2.4 billion in Q1 2022.
• A 5-year average of $3.2 billion and a median of $3.0 billion in 2024 frame the typical range for Current Assets.
• Annual changes were most pronounced in 2024 — Current Assets rose 3.43% — and 2026, when it surged 32.79%.
• Tracing BMRN's Current Assets over 5 years: stood at $2.8 billion in 2022, then rose by 7.44% to $3.0 billion in 2023, then gained by 9.35% to $3.2 billion in 2024, then advanced by 22.31% to $4.0 billion in 2025, then gained by 16.48% to $4.6 billion in 2026.
• Business Quant data shows BMRN's Current Assets at $4.6 billion in Q1 2026, $4.0 billion in Q4 2025, and $3.9 billion in Q3 2025.